Japan’s Astellas to buy Iveric Bio for $5.9 billion to expand eyesight treatments
By Rocky Swift TOKYO (Reuters) -Japan’s Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. The deal marks the fifth major overseas acquisition by Astellas, Japan’s third biggest drugmaker by sales, since 2019 …
Japan’s Astellas to buy Iveric Bio for $5.9 billion to expand eyesight treatments Read More »









